Figure 3.
(A): Induction of cytochrome c (Cyto c), but not apoptosis-inducing factor (AIF) release, from mitochondria in response to sorafenib treatment using HSP60 as a mitochondrial marker. (B) and (C): Untreated and sorafenib-treated PC-3 cells assayed for caspase-3 cleavage by immunocytochemical staining. (D): The contribution of caspase activation to the lethality of sorafenib treatment with or without the pan-caspase inhibitor Z-VAD-FMK (MTT assay).